抄録
HMG CoA reductase inhibitor or statin has been used for dyslipidemia for more than 10 years. Numerous clinical studies proved that it significantly reduces incidence of coronary heart diseases. The inhibition of HMG CoA reductase reduces de novo cholesterol production and also reduces the production of small GTP binding protein such as RhoA and RAS. Since biomembrane consists of huge amount of cholesterol, statin may also influence the membrane fluidity and thus signaling functions. Therefore intracellular signaling can be modulated by statin through cholesterol– dependent and –independent pathway.
